In conclusion, our results indicate that PI4KIIα knockdown reduces EGFR protein level in a degradation-dependent pathway, and the dual inhibition of EGFR protein level by PI4KIIα RNAi and EGFR activity by its specific small molecular inhibitors exerts superior outcomes for tumor therapy. Here, EGFR is linked to neoplasm.